English
简体中文
Total: £ 56.28
Published Date: 2026-01-22 | Pages: 111 | Tables: 113 | Medical Care
The global Value-added Medicines (VAM) market was valued at US$ 842 million in 2025 and is anticipated to reach US$ 1759 million by 2032, at a CAGR of 11.3% from 2026 to 2032.
Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
The North American market for Value-added Medicines (VAM) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Value-added Medicines (VAM) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Value-added Medicines (VAM) in Hospital is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Value-added Medicines (VAM) include Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Value-added Medicines (VAM) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Value-added Medicines (VAM). The Value-added Medicines (VAM) market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Value-added Medicines (VAM) market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Value-added Medicines (VAM) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Zentiva Group
MS Pharma
Towa International
CNX Therapeutics
ROVI
Elpen
Sandoz AG
Colonis
Adamed
Hyloris Pharmaceuticals SA
TIEFENBACHER GROUP
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Value-added Medicines (VAM) companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Market Perspective (2021–2032)
2.2 Global Value-added Medicines (VAM) Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Value-added Medicines (VAM) Historic Market Size by Region (2021–2026)
2.2.3 Value-added Medicines (VAM) Forecasted Market Size by Region (2027–2032)
2.3 Value-added Medicines (VAM) Market Dynamics
2.3.1 Value-added Medicines (VAM) Industry Trends
2.3.2 Value-added Medicines (VAM) Market Drivers
2.3.3 Value-added Medicines (VAM) Market Challenges
2.3.4 Value-added Medicines (VAM) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Players by Revenue (2021–2026)
3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Players (2021–2026)
3.2 Global Top Value-added Medicines (VAM) Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Revenue
3.4 Global Value-added Medicines (VAM) Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Revenue in 2025
3.5 Global Key Players of Value-added Medicines (VAM) Head Offices and Areas Served
3.6 Global Key Players of Value-added Medicines (VAM), Products and Applications
3.7 Global Key Players of Value-added Medicines (VAM), Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Historic Market Size by Type (2021–2026)
4.2 Global Value-added Medicines (VAM) Forecasted Market Size by Type (2027–2032)
5 Value-added Medicines (VAM) Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Historic Market Size by Application (2021–2026)
5.2 Global Value-added Medicines (VAM) Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Value-added Medicines (VAM) Market Size (2021–2032)
6.2 North America Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Value-added Medicines (VAM) Market Size by Country (2021–2026)
6.4 North America Value-added Medicines (VAM) Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Market Size (2021–2032)
7.2 Europe Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Value-added Medicines (VAM) Market Size by Country (2021–2026)
7.4 Europe Value-added Medicines (VAM) Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Market Size (2021–2032)
8.2 Asia-Pacific Value-added Medicines (VAM) Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2021–2026)
8.4 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Market Size (2021–2032)
9.2 Latin America Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Value-added Medicines (VAM) Market Size by Country (2021–2026)
9.4 Latin America Value-added Medicines (VAM) Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Market Size (2021–2032)
10.2 Middle East & Africa Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2021–2026)
10.4 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zentiva Group
11.1.1 Zentiva Group Company Details
11.1.2 Zentiva Group Business Overview
11.1.3 Zentiva Group Value-added Medicines (VAM) Introduction
11.1.4 Zentiva Group Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.1.5 Zentiva Group Recent Development
11.2 MS Pharma
11.2.1 MS Pharma Company Details
11.2.2 MS Pharma Business Overview
11.2.3 MS Pharma Value-added Medicines (VAM) Introduction
11.2.4 MS Pharma Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.2.5 MS Pharma Recent Development
11.3 Towa International
11.3.1 Towa International Company Details
11.3.2 Towa International Business Overview
11.3.3 Towa International Value-added Medicines (VAM) Introduction
11.3.4 Towa International Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.3.5 Towa International Recent Development
11.4 CNX Therapeutics
11.4.1 CNX Therapeutics Company Details
11.4.2 CNX Therapeutics Business Overview
11.4.3 CNX Therapeutics Value-added Medicines (VAM) Introduction
11.4.4 CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.4.5 CNX Therapeutics Recent Development
11.5 ROVI
11.5.1 ROVI Company Details
11.5.2 ROVI Business Overview
11.5.3 ROVI Value-added Medicines (VAM) Introduction
11.5.4 ROVI Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.5.5 ROVI Recent Development
11.6 Elpen
11.6.1 Elpen Company Details
11.6.2 Elpen Business Overview
11.6.3 Elpen Value-added Medicines (VAM) Introduction
11.6.4 Elpen Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.6.5 Elpen Recent Development
11.7 Sandoz AG
11.7.1 Sandoz AG Company Details
11.7.2 Sandoz AG Business Overview
11.7.3 Sandoz AG Value-added Medicines (VAM) Introduction
11.7.4 Sandoz AG Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.7.5 Sandoz AG Recent Development
11.8 Colonis
11.8.1 Colonis Company Details
11.8.2 Colonis Business Overview
11.8.3 Colonis Value-added Medicines (VAM) Introduction
11.8.4 Colonis Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.8.5 Colonis Recent Development
11.9 Adamed
11.9.1 Adamed Company Details
11.9.2 Adamed Business Overview
11.9.3 Adamed Value-added Medicines (VAM) Introduction
11.9.4 Adamed Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.9.5 Adamed Recent Development
11.10 Hyloris Pharmaceuticals SA
11.10.1 Hyloris Pharmaceuticals SA Company Details
11.10.2 Hyloris Pharmaceuticals SA Business Overview
11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Introduction
11.10.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.10.5 Hyloris Pharmaceuticals SA Recent Development
11.11 TIEFENBACHER GROUP
11.11.1 TIEFENBACHER GROUP Company Details
11.11.2 TIEFENBACHER GROUP Business Overview
11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Introduction
11.11.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2021–2026)
11.11.5 TIEFENBACHER GROUP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Value-added Medicines (VAM) Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Chronic Disease Treatment Drugs
Table 3. Key Players of Infectious Disease Treatment Drugs
Table 4. Key Players of Tumor Treatment Drugs
Table 5. Key Players of Other
Table 6. Global Value-added Medicines (VAM) Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Value-added Medicines (VAM) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Value-added Medicines (VAM) Market Size by Region (US$ Million), 2021–2026
Table 9. Global Value-added Medicines (VAM) Market Share by Region (2021–2026)
Table 10. Global Value-added Medicines (VAM) Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Value-added Medicines (VAM) Market Share by Region (2027–2032)
Table 12. Value-added Medicines (VAM) Market Trends
Table 13. Value-added Medicines (VAM) Market Drivers
Table 14. Value-added Medicines (VAM) Market Challenges
Table 15. Value-added Medicines (VAM) Market Restraints
Table 16. Global Value-added Medicines (VAM) Revenue by Players (US$ Million), 2021–2026
Table 17. Global Value-added Medicines (VAM) Market Share by Players (2021–2026)
Table 18. Global Top Value-added Medicines (VAM) Players by Tier (Tier 1, Tier 2, and Tier 3), based on Value-added Medicines (VAM) Revenue, 2025
Table 19. Ranking of Global Top Value-added Medicines (VAM) Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Value-added Medicines (VAM), Headquarters and Area Served
Table 22. Global Key Players of Value-added Medicines (VAM), Products and Applications
Table 23. Global Key Players of Value-added Medicines (VAM), Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Value-added Medicines (VAM) Market Size by Type (US$ Million), 2021–2026
Table 26. Global Value-added Medicines (VAM) Revenue Market Share by Type (2021–2026)
Table 27. Global Value-added Medicines (VAM) Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Value-added Medicines (VAM) Revenue Market Share by Type (2027–2032)
Table 29. Global Value-added Medicines (VAM) Market Size by Application (US$ Million), 2021–2026
Table 30. Global Value-added Medicines (VAM) Revenue Market Share by Application (2021–2026)
Table 31. Global Value-added Medicines (VAM) Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Value-added Medicines (VAM) Revenue Market Share by Application (2027–2032)
Table 33. North America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026
Table 35. North America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Value-added Medicines (VAM) Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032
Table 48. Zentiva Group Company Details
Table 49. Zentiva Group Business Overview
Table 50. Zentiva Group Value-added Medicines (VAM) Product
Table 51. Zentiva Group Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 52. Zentiva Group Recent Development
Table 53. MS Pharma Company Details
Table 54. MS Pharma Business Overview
Table 55. MS Pharma Value-added Medicines (VAM) Product
Table 56. MS Pharma Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 57. MS Pharma Recent Development
Table 58. Towa International Company Details
Table 59. Towa International Business Overview
Table 60. Towa International Value-added Medicines (VAM) Product
Table 61. Towa International Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 62. Towa International Recent Development
Table 63. CNX Therapeutics Company Details
Table 64. CNX Therapeutics Business Overview
Table 65. CNX Therapeutics Value-added Medicines (VAM) Product
Table 66. CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 67. CNX Therapeutics Recent Development
Table 68. ROVI Company Details
Table 69. ROVI Business Overview
Table 70. ROVI Value-added Medicines (VAM) Product
Table 71. ROVI Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 72. ROVI Recent Development
Table 73. Elpen Company Details
Table 74. Elpen Business Overview
Table 75. Elpen Value-added Medicines (VAM) Product
Table 76. Elpen Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 77. Elpen Recent Development
Table 78. Sandoz AG Company Details
Table 79. Sandoz AG Business Overview
Table 80. Sandoz AG Value-added Medicines (VAM) Product
Table 81. Sandoz AG Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 82. Sandoz AG Recent Development
Table 83. Colonis Company Details
Table 84. Colonis Business Overview
Table 85. Colonis Value-added Medicines (VAM) Product
Table 86. Colonis Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 87. Colonis Recent Development
Table 88. Adamed Company Details
Table 89. Adamed Business Overview
Table 90. Adamed Value-added Medicines (VAM) Product
Table 91. Adamed Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 92. Adamed Recent Development
Table 93. Hyloris Pharmaceuticals SA Company Details
Table 94. Hyloris Pharmaceuticals SA Business Overview
Table 95. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product
Table 96. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 97. Hyloris Pharmaceuticals SA Recent Development
Table 98. TIEFENBACHER GROUP Company Details
Table 99. TIEFENBACHER GROUP Business Overview
Table 100. TIEFENBACHER GROUP Value-added Medicines (VAM) Product
Table 101. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026
Table 102. TIEFENBACHER GROUP Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Value-added Medicines (VAM) Picture
Figure 2. Global Value-added Medicines (VAM) Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Value-added Medicines (VAM) Market Share by Type: 2025 vs 2032
Figure 4. Chronic Disease Treatment Drugs Features
Figure 5. Infectious Disease Treatment Drugs Features
Figure 6. Tumor Treatment Drugs Features
Figure 7. Other Features
Figure 8. Global Value-added Medicines (VAM) Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Value-added Medicines (VAM) Market Share by Application: 2025 vs 2032
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Other Case Studies
Figure 13. Value-added Medicines (VAM) Report Years Considered
Figure 14. Global Value-added Medicines (VAM) Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Value-added Medicines (VAM) Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Value-added Medicines (VAM) Market Share by Region: 2025 vs 2032
Figure 17. Global Value-added Medicines (VAM) Market Share by Players in 2025
Figure 18. Global Value-added Medicines (VAM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Revenue in 2025
Figure 20. North America Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Value-added Medicines (VAM) Market Share by Country (2021–2032)
Figure 22. United States Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Value-added Medicines (VAM) Market Share by Country (2021–2032)
Figure 26. Germany Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Value-added Medicines (VAM) Market Share by Region (2021–2032)
Figure 34. China Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Value-added Medicines (VAM) Market Share by Country (2021–2032)
Figure 42. Mexico Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Share by Country (2021–2032)
Figure 46. Israel Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Zentiva Group Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 50. MS Pharma Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 51. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 52. CNX Therapeutics Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 53. ROVI Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 54. Elpen Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 55. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 56. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 57. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 58. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 59. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
